CHATSWORTH, CA / ACCESSWIRE / October 1, 2018 / With the successful completion of our biodiesel system trial unit in Colombia, Cavitation Technologies, Inc. (OTCQB: CVAT) (BERLIN: WTC) recorded revenue in the first quarter of fiscal 2019. The biodiesel production system trial unit has gone through vigorous testing over the past year, with final results meeting the customer's demand and expectations.
"We have successfully completed the biodiesel system trial in South America. We were able to achieve positive results by reducing catalyst consumption as high as fifteen percent, while maintaining a good quality of biodiesel, provided consistent stability of operations. flexibility in various usage of feedstock, glycerin separation and reduction of monoglycerides in the final product. Our expectations are to monetize on a new commercial application for production of biodiesel by providing the industry with an innovative technology and look forward to install new systems in our fiscal 2019," concluded Mr. Roman Gordon, Global Technology Manager at CTi.
About CTi
Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algal oil extraction, alcoholic beverage enhancement, water treatment, and the extraction of cannabidiol (CBD). As an add-on to its existing neutralization systems, the company's patented Nano Reactor™ allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield. http://www.ctinanotech.com/
Follow us on Twitter for real time updates: https://twitter.com/CavitationTech
Like us on Facebook to receive live feed updates: https://www.facebook.com/ctinanotech
Check us out on LinkedIn: https://www.linkedin.com/company/cavitation-technologies
Forward Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Cavitation Technologies, Inc.
Contact:
Investor Relations
[email protected]
Phone (818) 718-0905
SOURCE: Cavitation Technologies, Inc.